• Natera reported first patient enrollment in a randomized melanoma trial using its Signatera test to guide treatment escalation.
• Results have not been presented; the study will assess whether earlier therapy intensification improves outcomes versus continuing standard immunotherapy.
• Trial targets advanced or metastatic melanoma patients with persistent molecular residual disease despite initial treatment, before scans show progression.
• Readout could support broader adoption of ctDNA-guided decision-making in melanoma, expanding Signatera’s clinical utility beyond monitoring.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Natera Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610070800BIZWIRE_USPR_____20261007_BW356370) on October 07, 2026, and is solely responsible for the information contained therein.